Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) posted its quarterly earnings results on Tuesday. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 62.10%. Get Cyclerion Therapeutics alerts:Hedge Funds Weigh In On Cyclerion TherapeuticsA hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics as of its most recent filing with the SEC. Further ReadingReceive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.